Biological response modifiers of cancer-related neuroendocrine disorders: Efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 3-4, 2004, Pages 291-294

  Lissoni, Paolo ^a   Vaghi, M ^a   Pescia, S ^a   Rovelli, F ^a   Ardizzola, A ^a   Valtulina, F ^a   Malugani, F ^a   Gardani, G ^a   Tancini, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Breast cancer; Cabergoline; Dopamine agonists; Hyperprolactinemia

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; SEX HORMONE; ERGOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; NAUSEA; NEUROENDOCRINE DISEASE; PROGNOSIS; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISEASE; TREATMENT PLANNING; BLOOD; BREAST TUMOR; MIDDLE AGED;

AGED; BREAST NEOPLASMS; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PROLACTIN;

EID: 17844375929     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Holtkamp W, Nagel CA, Wander HE, Rauschecker HF, Meyden C. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 1984; 34: 323-8.
2. Wang DY, Hampson S, Kwa HG. Serum prolactin levels in women with breast cancer and their relationship to survival. Eur J Cancer Clin Oncol 1986; 22: 487-92.
3. Barni S, Lissoni P, Tancini G, et al. Prolactin response to thyrotropin-releasing hormone in early and advanced breast cancer. Tumori 1986; 72: 399-403.
4. Welsch C, Nagasawa H. Prolactin and murine tumorigenesis: a review. Cancer Res 1977; 37: 951-63.
5. Cussenot O. Growth factors and prostatic tumors. Ann Endocrinol 1997; 58: 370-80.
6. Lissoni P, Vaghi M, Ardizzoia A, et al. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuroendocrinol Lett 2001; 22: 27-9.
7. Barni S, Lissoni P, Meregalli S, et al. Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Tumori 1998; 84: 45-7.
8. Jankovic BD. Neuroimmunomodulation. Ann NY Acad Sci 1994; 741: 3-38.
9. Lissoni P, Mandalà M, Giani L, et al. Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia. Neuroendocrinol Lett 2000; 21: 405-8.
10. Ben-Jonathan N. Dopamine: A prolactin-inhibiting hormone. Endocr Rev 1985; 6: 564-89.
11. Tumosito J. Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985; 37: 249-332.
12. Lissoni P, Bucovec R, Malugani F, et al. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracycline. Anticancer Res 2002; 22: 1131-4.